Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: Demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques

被引:4
作者
Dasgupta, A
Vega, AE
Wells, A
Datta, P
机构
[1] Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA
[2] Bayer Diagnost, E Walpole, MA USA
关键词
free digitoxin; fluorescence polarization; chemiluminescent assay; phenytoin;
D O I
10.1097/00007691-199912000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Digitoxin is very strongly bound to serum albumin. Although free digitoxin is pharmacologically active, it is not monitored because of the lack of a sufficiently sensitive technique. The concentration of free digitoxin in the protein-free ultrafiltrate is usually below the detection limit of digitoxin immunoassays. A modified technique is described by which free digitoxin can be routinely monitored using commercially available immunoassays. The fluorescence polarization immunoassay for determining total digitoxin concentration requires that 100 mu L of serum be treated with 300 mu L of methanol to precipitate proteins. It is demonstrated that free digitoxin can easily be measured by adding 100 mu L Of methanol to 300 mu L of ultrafiltrate, thus improving the sensitivity of the assay three-fold. The free digitoxin concentration can easily be calculated by dividing the observed value by 3. An attempt to use only ultrafiltrate (no methanol added) caused significant bias in the result, probably as a result of a matrix problem. The chemiluminescent assay for digitoxin does not require any specimen pretreatment and requires only 10 mu L of serum. The program was modified and used 50 mu L of ultrafiltrate to improve the sensitivity of the free digitoxin assay. If the chemiluminescent assay is used to measure free digitoxin, the true free digitoxin concentration can be calculated by dividing the observed value by 4.3. The free digitoxin concentrations were comparable in eight patients receiving digitoxin as measured by both methods. To show an application of this technique, two serum pools were prepared from patients receiving digitoxin and supplemented with various concentrations of phenytoin. A significant increase in free digitoxin concentration was observed because of the displacement of digitoxin from protein binding sites by phenytoin.
引用
收藏
页码:625 / 630
页数:6
相关论文
共 15 条
[1]  
Aass H, 1997, Tidsskr Nor Laegeforen, V117, P2032
[2]   EVALUATION OF AN ULTRAFILTRATION FLUORESCENCE POLARIZATION IMMUNOASSAY FOR MONITORING UNBOUND PHENYTOIN [J].
ARGYLE, JC ;
KINNIBURGH, DW ;
COSTA, R ;
JENNISON, T .
THERAPEUTIC DRUG MONITORING, 1984, 6 (01) :117-120
[3]   PROBLEMS IN THERAPEUTIC DRUG-MONITORING - FREE DRUG LEVEL MONITORING [J].
BARRE, J ;
DIDEY, F ;
DELION, F ;
TILLEMENT, JP .
THERAPEUTIC DRUG MONITORING, 1988, 10 (02) :133-143
[4]   Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: Lack of interaction in uremic sera due to the presence of endogenous factors [J].
Dasgupta, A ;
Emerson, L .
THERAPEUTIC DRUG MONITORING, 1996, 18 (06) :654-659
[5]   FAST-ATOM-BOMBARDMENT MASS-SPECTROMETRIC DETERMINATION OF THE MOLECULAR-WEIGHT RANGE OF UREMIC COMPOUNDS THAT DISPLACE PHENYTOIN FROM PROTEIN-BINDING - ABSENCE OF MIDMOLECULAR UREMIC TOXINS [J].
DASGUPTA, A ;
MALIK, S .
AMERICAN JOURNAL OF NEPHROLOGY, 1994, 14 (03) :162-168
[6]   Plasma total phenytoin: A possibly misleading test in developing countries [J].
Fedler, C ;
Stewart, MJ .
THERAPEUTIC DRUG MONITORING, 1999, 21 (02) :155-160
[7]   DISPLACEMENT OF PHENYTOIN FROM PLASMA-BINDING SITES BY SALICYLATE [J].
FRASER, DG ;
LUDDEN, TM ;
EVENS, RP ;
SUTHERLAND, EW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (02) :165-169
[8]   CARDIAC-GLYCOSIDES [J].
KOREN, G ;
SOLDIN, SJ .
CLINICS IN LABORATORY MEDICINE, 1987, 7 (03) :587-606
[9]  
LARSEN A, 1973, CLIN PHARMACOL THER, V19, P387
[10]   INTERACTION BETWEEN VALPROIC ACID AND ASPIRIN IN EPILEPTIC CHILDREN - SERUM-PROTEIN BINDING AND METABOLIC EFFECTS [J].
ORR, JM ;
ABBOTT, FS ;
FARRELL, K ;
FERGUSON, S ;
SHEPPARD, I ;
GODOLPHIN, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (05) :642-649